Award
National Cancer Institute 4R37CA248018-06
Leveraging the GTP Biosynthetic Pathway for Anti-Tumor Therapies
Recipient
Roswell Park Cancer Institute Corp
Award Amount
$396,881.00
Ceiling
$396,881.00
Awarded
April 28, 2026
Identifier
4R37CA248018-06
Research project funded by the National Cancer Institute to explore GTP metabolic pathways and their regulation to develop targeted therapies against metastatic triple-negative breast cancer.
Description
This research aims to identify novel metabolic vulnerabilities to suppress triple-negative breast cancer (TNBC) invasiveness and metastasis, focusing on GTP metabolism and its enzymes, particularly IMPDH2, and transcriptional regulation by factors such as KLF9 and AHR.